Senetek PLC Enters Into Licensing Agreement With Vivier Pharma Inc.
Tuesday October 22, 8:17 am ET
- Senetek Obtains Rights to Vivier Proprietary Technology -
NAPA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), ( www.senetekplc.com ), and Vivier Pharma Inc., of Montreal, Canada, ( www.vivierpharma.com ), today announced the signing of a license agreement granting Vivier the right to manufacture and sell to dermatologists, pharmacies and other ethical channels in Canada and the United States dermatological products containing Senetek's patented Kinetin skin care ingredient in combination with Vivier's proprietary formulation of Vitamin C (L-Ascorbic Acid). Vivier expects to launch in early 2003.
In addition, Vivier has granted Senetek the right to sell, and license others to sell, these combination products as well as Vivier's line of Vitamin C serums in most markets worldwide. The Agreement calls for the parties to collaborate on future developmental projects and clinical evaluations.
Frank J. Massino, Chairman and Chief Executive Officer of Senetek, said, "We are delighted to be joining forces with Vivier Pharma to maximize the global opportunity for this remarkable line of combination dermatologicals and collaborate with this innovative firm on the development of other exciting products."
Jess Vivier, President and Chief Executive Officer of Vivier Pharma, commented, "The combination of Kinetin with our proprietary, stable form of Vitamin C is very exciting. We believe this can be the next blockbuster anti-aging topical on the market."
Vivier Pharma Inc. is an emerging biopharmaceutical research, development and marketing company in the field of cosmetic dermatology. Its Vitamin C Serums are sold in Canada, the United States and several other countries including Japan. Vivier Pharma, which will produce all of the products covered by the new license agreement, manufactures strictly in accordance with prescription pharmaceutical standards.
Senetek PLC is a biopharmaceutical company focused on developing and co-marketing products in the key skin care/dermatologicals and sexual dysfunction categories worldwide. Its patented Kinetin ingredient, a naturally occurring cytokinin which acts to retard cell aging in plants, has been licensed to some nine other companies with leading positions in their fields including Revlon, ICN Pharmaceuticals and The Body Shop.
Visit Senetek PLC's web site: senetekplc.com .
Investor Relations Contact:
1-707-226-3900 ext. 102
E-Mail: Pknopick@eandecommunications.com
Safe Harbor Statement:
This news release may contain statements that may be considered "forward- looking statements" under the Federal securities laws, including statements concerning the revenue and licensing income the Company may receive in the future under licenses of the Company's products, and the additional licensing agreements the Company may enter into during 2002. No forward-looking statement the Company makes is a guarantee of future performance or events. Actual results or events may differ materially from those in the forward- looking statements as a result of various factors, including the risks and uncertainties described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and Quarterly Report on Form 10-Q for the three months ended June 30, 2002, filed with the Securities and Exchange Commission.
Make Your Opinion Count - Click Here
--------------------------------------------------------------------------------
Source: Senetek PLC |
